» Articles » PMID: 33822106

Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China

Overview
Journal J Infect Dis
Date 2021 Apr 6
PMID 33822106
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postdischarge immunity and its correlation with clinical features among patients recovered from coronavirus disease 2019(COVID-19) are poorly described. This prospective cross-sectional study explored the inflammatory profiles and clinical recovery of patients with COVID-19 at 3 months after hospital discharge.

Methods: Patients with COVID-19 discharged from 4 hospitals in Wuhan, recovered asymptomatic patients (APs) from an isolation hotel, and uninfected healthy controls (HCs) were recruited. Viral nucleic acid and antibody detection, laboratory examination, computed tomography, pulmonary function assessment, multiplex cytokine assay, and flow cytometry were performed.

Results: The72 age-, sex- and body mass index-matched participants included 19 patients with severe/critical COVID-19 (SPs), 20 patients with mild/moderate COVID-19 (MPs), 16 APs, and 17 HCs. At 3 months after discharge, levels of proinflammatory cytokines and factors related to vascular injury/repair in patients recovered from COVID-19 had not returned to those of the HCs, especially among recovered SPs compared with recovered MPs and APs. These cytokines were significantly correlated with impaired pulmonary function and chest computed tomographic abnormalities. However, levels of immune cells had returned to nearly normal levels and were not significantly correlated with abnormal clinical features.

Conclusion: Vascular injury, inflammation, and chemotaxis persisted in patients with COVID-19 and were correlated with abnormal clinical features 3 months after discharge, especially in recovered SPs.

Citing Articles

Mechanisms of long COVID and the path toward therapeutics.

Peluso M, Deeks S Cell. 2024; 187(20):5500-5529.

PMID: 39326415 PMC: 11455603. DOI: 10.1016/j.cell.2024.07.054.


Objective and subjective cognitive outcomes one year after COVID-19.

Zamarian L, Rass V, Goettfried E, Mayr V, Carbone F, Kindl P Ann Clin Transl Neurol. 2024; 11(9):2360-2371.

PMID: 39031013 PMC: 11537146. DOI: 10.1002/acn3.52149.


Clinical and pulmonary function analysis in long-COVID revealed that long-term pulmonary dysfunction is associated with vascular inflammation pathways and metabolic syndrome.

Sanhueza S, Vidal M, Hernandez M, Henriquez-Beltran M, Cabrera C, Quiroga R Front Med (Lausanne). 2023; 10:1271863.

PMID: 37869162 PMC: 10590130. DOI: 10.3389/fmed.2023.1271863.


Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19.

Carpio C, Qasem A, Buno A, Borobia A, Arnalich F, Rey V J Clin Med. 2023; 12(19).

PMID: 37834944 PMC: 10573402. DOI: 10.3390/jcm12196299.


Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms.

Xu Z, Wang H, Jiang S, Teng J, Zhou D, Chen Z Neurosci Bull. 2023; 40(3):383-400.

PMID: 37715924 PMC: 10912108. DOI: 10.1007/s12264-023-01110-0.